ReviewFrontiers in medicine2017
Therapeutic Application of Pluripotent Stem Cells: Challenges and Risks.
Review in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 74 citations in OpenAlex.
- Scale-down optimization of a robust, parallelizable human induced pluripotent stem cell bioprocess for high-throughput research.Biotechnology reports (Amsterdam, Netherlands) · 2025Article
- Clinical Applications of Corneal Cells Derived from Induced Pluripotent Stem Cells.Biomolecules · 2025Review
- Transformative Potential of Induced Pluripotent Stem Cells in Congenital Heart Disease Research and Treatment.Children (Basel, Switzerland) · 2025Review
- Innovative approaches in neural stem cell therapy: a comprehensive review of mechanisms and applications.American journal of stem cells · 2025Review
- Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Current medicinal chemistry · 2024Review
- Advanced therapy to cure diabetes: mission impossible is now possible?Frontiers in cell and developmental biology · 2024Review
- Human pluripotent stem cell-derived extracellular vesicles: From now to the future.World journal of stem cells · 2023Review
- Label-free optical imaging and sensing for quality control of stem cell manufacturing.Current opinion in biomedical engineering · 2023Article
- Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors.Stem cell reports · 2022Article
- Current Progress in the Creation, Characterization, and Application of Human Stem Cell-derived in Vitro Neuromuscular Junction Models.Stem cell reviews and reports · 2022Review
- Induced pluripotent stem cells: Generation methods and a new perspective in COVID-19 research.Frontiers in cell and developmental biology · 2022Review
- Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis.Stem cell research & therapy · 2021Article
- Human pluripotent stem cells for the modelling and treatment of respiratory diseases.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Cell therapy strategies for COVID-19: Current approaches and potential applications.Science advances · 2021Review
- SimplifiedPharmaceutics · 2021Article
- Perspectives of pluripotent stem cells in livestock.World journal of stem cells · 2021Review
- Review
- Novel therapies using cell sheets engineered from allogeneic mesenchymal stem/stromal cells.Emerging topics in life sciences · 2020Review
- Inhibition of FGF and TGF-β Pathways in hESCs Identify STOX2 as a Novel SMAD2/4 Cofactor.Biology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem-cell-based therapies are considered to be promising and innovative but complex approaches. Induced pluripotent stem cells (iPSCs) combine the advantages of adult stem cells with the hitherto unique characteristics of embryonic stem cells (ESCs). Major progress has already been achieved with regard to reprogramming technology, but also regarding targeted genome editing and scalable expansion and differentiation of iPSCs and ESCs, in some cases yielding highly enriched preparations of well-defined cell lineages at clinically required dimensions. It is noteworthy, however, that for many applications critical requirements such as the targeted specification into distinct cellular subpopulations and a proper cell maturation remain to be achieved. Moreover, current hurdles such as low survival rates and insufficient functional integration of cellular transplants remain to be overcome. Nevertheless, PSC technologies obviously have come of age and matured to a stage where various clinical applications of PSC-based cellular therapies have been initiated and are conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.